Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT04129034 Active, not recruiting - Clinical trials for Facet Syndrome of Lumbar Spine

Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain

Start date: September 24, 2019
Phase: N/A
Study type: Interventional

Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a high intensity focused ultrasound device, for non-invasive treatment of axial chronic low back pain

NCT ID: NCT04128969 Recruiting - Metabolic Syndrome Clinical Trials

Causal Mechanisms in Adolescent Arterial Stiffness

Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

Hardening of the blood vessels, called arterial stiffness, is a risk factor for future heart disease and its causes are unclear. The proposed study will 1) randomly assign adolescents at high risk of stiffening blood vessels to take a protein supplement called carnitine and study its effects on arterial stiffening and 2) study carnitine related genes for their effect on arterial stiffening. The study will definitively establish a role for carnitine action as a cause of stiffening blood vessels and signal a way to treat or prevent stiffening.

NCT ID: NCT04128748 Recruiting - Clinical trials for Acute Myeloid Leukemia

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Start date: May 27, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The goal of this study is to learn if the combination of CPX-351 and quizartinib can help to control acute myeloid leukemia and myelodysplastic syndrome.

NCT ID: NCT04128059 Recruiting - Clinical trials for MERS (Middle East Respiratory Syndrome)

Study of Safety and Immunogenicity of BVRS-GamVac-Combi

Start date: November 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.

NCT ID: NCT04126434 Recruiting - Clinical trials for Acute Coronary Syndrome

Intervention of Air Pollution and Acute Coronary Syndrome

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

To determine the effect of intervention of ambient air pollution on acute coronary syndrome patients.

NCT ID: NCT04125914 Active, not recruiting - Lynch Syndrome Clinical Trials

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

Start date: January 26, 2017
Phase: N/A
Study type: Interventional

This trial studies how well weight management and health behavior intervention works in helping patients with hereditary breast and ovarian cancer and Lynch syndrome mutation carriers lose or maintain a healthy weight and lower their risk for cancer. Lifestyle behaviors such as physical activity, diet, and weight management may play a key role in preventing cancers and improving outcomes even in those with hereditary cancer syndromes.

NCT ID: NCT04124471 Completed - Clinical trials for Obstructive Sleep Apnea

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)

Start date: August 2, 2019
Phase: N/A
Study type: Interventional

To identify the perceptions, beliefs, and family-relevant outcomes regarding the treatment of obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) in children with Down's Syndrome (DS).

NCT ID: NCT04124237 Completed - Long QT Syndrome Clinical Trials

Long Term Monitoring for Risk of Sudden Death

Start date: May 15, 2015
Phase:
Study type: Observational [Patient Registry]

Risk prediction in in inherited heart rhythm conditions that may cause sudden cardiac arrest or death is difficult. Sometimes the risks may be low but the loss of life in an otherwise healthy young individual is catastrophic. Clinicians often treat to the extreme to prevent this and so often those at unknown risk for a serious cardiac event are treated with an implanted cardioverter defibrillator (ICD) to protect against sudden death even though the risk is low or unknown. ICDs them selves are not without adverse events such as needing battery replacements, mechanical complications, inappropriate shocks and body image and self esteem issues for the patient. This study will use an inject able monitor that is less invasive to monitor inherited heart rhythm patients long term to help gather long term heart rhythm data (3 years) on patients with an inherited heart rhythm that will help to detect symptoms of dangerous heart rhythms so that the appropriate care can be provided.

NCT ID: NCT04123483 Withdrawn - Clinical trials for Premenstrual Syndrome

EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders

Start date: November 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess a novel nutritional supplement developed for prenatal health and mood benefits, and to determine whether there is preliminary evidence for efficacy in Menstrual Related Mood Disorders (MRMD), including PMS with Prominent Mood Symptoms and PMDD.

NCT ID: NCT04123132 Recruiting - Metabolic Syndrome Clinical Trials

Evaluation of Kinesophobia in Patients With Metabolic Syndrome

Start date: September 25, 2019
Phase:
Study type: Observational

Metabolic syndrome (MS) is a public health problem characterized by central obesity, increased blood pressure and triglyceride levels, decreased blood HDL levels and the presence of insulin resistance (1).Kinesiophobia is a fear of irrational movement that develops because of its belief in susceptibility to injury and is associated with low levels of physical activity. Considering that exercise improves metabolic processes in people with MS, we aimed to evaluate the presence of kinesophobia in patients with MS. Patients aged 45-65 years diagnosed with metabolic syndrome and healthy controls will be included in the study. Patients with rheumatic and neurological diseases,history of trauma, gonarthrosis, lumbar disc hernia, previous fractures, fibromyalgia and those who have experienced pain for the last week will be excluded. The participants will be filled in the Short Form-36 (SF-36), the Hospital Anxiety and Depression Scale, and the Tampa Kinesiophobia Scale. 48 patients with MS and 48 healthy participants will be included in the study.